These include an increased production of inhibitor-sensitive proteinases, or the synthesis of novel inhibitor-insensitive proteinases.
The reasons for the dominance of kinase (and other enzyme) inhibitors as targets for modern cancer therapeutics are centred on the enzyme substrate-binding site.
This question has been addressed using specific inhibitors of individual components of the response pathways.
Results obtained with inhibitors have been expressed as a percentage of the control to enhance interpretation in fig. 1a.
Results are expressed as the percentage of residual activity of the enzyme against the concentration of the inhibitor.
Values are expressed relative to a control mixture which was incubated with no trypsin or inhibitor.
This inhibitor has been demonstrated in whole worm extracts and in the incubation medium of in m£ro-maintained, intact living metacestodes.
Better adjustments in concentration of inhibitors, drug combinations and/or culture conditions might be necessary to improve the efficiency of these drugs.
